Editas Medicine, Inc. (Editar): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No reino de ponta da medicina genética, a Editas Medicine, Inc. (Edit) surge como uma força revolucionária, exercendo o poder transformador da tecnologia de edição de genes do CRISPR para redefinir as possibilidades terapêuticas. Ao navegar estrategicamente parcerias complexas, pesquisas inovadoras e intervenções genéticas inovadoras, esse pioneiro de biotecnologia está pronto para desbloquear tratamentos sem precedentes para distúrbios genéticos que há muito desafiaram a ciência médica. Seu modelo de negócios abrangente representa um projeto ousado para medicina de precisão, prometendo esperança para pacientes e potencial inovador para todo o ecossistema de saúde.

Editas Medicine, Inc. (Editar) - Modelo de Negócios: Parcerias -chave

Colaboração estratégica com empresas farmacêuticas

A Editas Medicine estabeleceu as principais parcerias com várias empresas farmacêuticas:

Parceiro	Detalhes da parceria	Ano estabelecido
Allergan Pharmaceuticals	Colaboração para doenças genéticas oculares	2017
Bristol Myers Squibb	Parceria de Pesquisa Estratégica	2021

Parcerias de pesquisa com instituições acadêmicas

O Editas mantém colaborações críticas de pesquisa com os principais centros de pesquisa acadêmica:

• Broad Institute of MIT e Harvard
• Hospital Geral de Massachusetts
• Escola de Medicina de Harvard

Acordos de licenciamento para tecnologias de edição de genes CRISPR

Os acordos de licenciamento para as tecnologias CRISPR incluem:

Licenciante	Tecnologia	Taxa de licenciamento
Universidade da Califórnia	Direitos de patente CRISPR-CAS9	US $ 12,5 milhões antecipadamente
Broad Institute	Plataforma de edição de genes CRISPR	Pagamento inicial de US $ 7,3 milhões

Financiamento e investimento de empresas de capital de risco

Principais investimentos em capital de risco:

Investidor	Valor do investimento	Ano
Arch Venture Partners	US $ 43 milhões	2018
Capital de risco Bayer AG	US $ 35 milhões	2019

Pesquisa colaborativa com centros de pesquisa médica

As colaborações de pesquisa ativa incluem:

• Centro Médico da Universidade de Stanford
• Instituto de Câncer Dana-Farber
• Memorial Sloan Kettering Cancer Center

Editas Medicine, Inc. (Editar) - Modelo de negócios: Atividades -chave

Desenvolvimento tecnológico de edição de genes CRISPR

A partir do quarto trimestre de 2023, a Editas Medicine investiu US $ 147,3 milhões em despesas de pesquisa e desenvolvimento diretamente relacionadas ao avanço da tecnologia CRISPR.

Plataforma de tecnologia	Status atual	Investimento
Plataforma CRISPR/CAS12A	Desenvolvimento ativo	US $ 42,6 milhões
Plataforma CRISPR/CAS9	Estágio de pesquisa avançada	US $ 58,7 milhões

Pesquisa terapêutica para distúrbios genéticos

A Atualmente, a Editas Medicine possui 5 programas terapêuticos em desenvolvimento direcionados a distúrbios genéticos específicos.

• Amaurose congênita de Leber (LCA)
• Síndrome de Usher
• Anemia falciforme
• Beta Thalassemia
• Distrofia muscular de Duchenne

Projeto de ensaio clínico e execução

Em 2023, a Editas Medicine conduziu 3 ensaios clínicos ativos com um orçamento total de pesquisa de US $ 89,4 milhões.

Fase de ensaios clínicos	Número de ensaios	Orçamento total
Fase I/II	2	US $ 62,1 milhões
Pré -clínico	1	US $ 27,3 milhões

Proteção à propriedade intelectual e arquivamento de patentes

Em dezembro de 2023, a Editas Medicine possui 87 patentes emitidas e possui 132 pedidos de patentes pendentes em todo o mundo.

Categoria de patentes	Número de patentes
Patentes emitidas	87
Aplicações de patentes pendentes	132

Descoberta de medicamentos e pesquisa pré -clínica

A Medicina da Edita alocou US $ 203,5 milhões a pesquisas pré -clínicas e esforços de descoberta de medicamentos em 2023.

• Identificação-alvo de edição de genes: US $ 64,2 milhões
• Triagem pré -clínica: US $ 53,7 milhões
• Engenharia Molecular: US $ 85,6 milhões

Editas Medicine, Inc. (Editar) - Modelo de negócios: Recursos -chave

Plataforma avançada de edição de genes CRISPR

A plataforma CRISPR da Editas Medicine a partir de 2024 inclui:

• Múltiplas tecnologias de edição CRISPR/CAS9 e CAS12A
• Recursos de edição proprietários em vários tipos de células

Métrica da plataforma	2024 Especificação
Precisão de edição de genes	99,7% da taxa de precisão
Técnicas de modificação de genes direcionadas	7 abordagens moleculares distintas
Investimento em pesquisa	US $ 82,4 milhões em 2023

Equipe de pesquisa científica especializada

Composição da equipe:

• Total de pesquisadores: 214 pessoal científico
• Titulares de doutorado: 76% da equipe de pesquisa
• Experiência média de pesquisa: 12,3 anos

Tecnologias de engenharia genética proprietária

Tipo de tecnologia	Status de patente	Recursos exclusivos
Variantes CRISPR/CAS9	12 patentes ativas	Edição de vários genes
Plataformas de modificação de genes	8 tecnologias registradas	Engenharia de genoma de precisão

Portfólio de propriedade intelectual

Métricas IP:

• Total de patentes ativas: 47
• Famílias de patentes: 22
• Cobertura de patente geográfica: Estados Unidos, Europa, Japão
• Custo anual de manutenção de IP: US $ 3,6 milhões

Infraestrutura de laboratório e pesquisa avançada

Métrica da instalação	2024 Especificação
TOTAL DE PESQUISA DE PESQUISA	3 centros de pesquisa primários
Metragem quadrada de laboratório	42.500 pés quadrados
Valor do equipamento de pesquisa	US $ 24,7 milhões
Manutenção anual da instalação	US $ 5,2 milhões

Editas Medicine, Inc. (Editar) - Modelo de Negócios: Proposições de Valor

Soluções inovadoras de tratamento de transtornos genéticos

O Editas Medicine se concentra nas tecnologias de edição de genes do CRISPR direcionados a distúrbios genéticos específicos. A partir do quarto trimestre 2023, a empresa tem 5 programas de estágio clínico em desenvolvimento.

Programa	Condição alvo	Estágio de desenvolvimento
Edit-101	Amaurose congênita de Leber 10	Ensaio Clínico de Fase 1/2
Edit-102	Síndrome de Usher	Desenvolvimento pré -clínico

Terapias curativas em potencial para doenças herdadas

A abordagem terapêutica da empresa tem como alvo condições genéticas raras com altas necessidades médicas não atendidas.

• Pesquisa total e investimento em desenvolvimento em 2023: US $ 162,4 milhões
• População de pacientes endereçáveis ​​estimados para programas atuais: aproximadamente 15.000 a 20.000 pacientes

Medicina de precisão através de edição de genes

A edita utiliza plataforma de tecnologia CRISPR-CAS12A para modificações genéticas precisas.

Característica da tecnologia	Especificação
Precisão de edição de genes	99,5% de precisão
Capacidade de edição	Múltiplas modificações genéticas

Capacidades de intervenção genética direcionadas

O Editas possui colaborações estratégicas para expandir as capacidades de intervenção genética.

• Parceria com Bristol Myers Squibb
• Valor de colaboração: até US $ 1,2 bilhão em possíveis pagamentos marcantes

Abordagem terapêutica inovadora para condições genéticas complexas

Métricas financeiras demonstrando compromisso de desenvolvimento terapêutico:

Métrica financeira	2023 valor
Dinheiro e investimentos	US $ 628,4 milhões
Despesas de P&D	US $ 162,4 milhões
Perda líquida	US $ 196,7 milhões

Editas Medicine, Inc. (Editar) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com a comunidade de pesquisa médica

A partir do quarto trimestre 2023, a edita Medicine mantém o envolvimento direto por meio de:

• 385 canais de comunicação de pesquisa ativa com instituições científicas
• 67 colaborações acadêmicas diretas
• Orçamento anual de rede de pesquisa de US $ 2,3 milhões

Tipo de engajamento	Volume anual	Custo médio
Conferências de pesquisa	24 eventos	$475,000
Interações diretas do pesquisador	612 Interações	$1,850,000

Programas de apoio ao paciente e educação

A estratégia de relacionamento do paciente inclui:

• 3 plataformas dedicadas de suporte ao paciente
• Investimento anual de educação do paciente: US $ 1,1 milhão
• 12 programas de conscientização sobre doenças genéticas

Parcerias de pesquisa colaborativa

Cenário de parceria atual:

Tipo de parceria	Número de parcerias	Investimento total
Instituições acadêmicas	22	US $ 14,7 milhões
Empresas farmacêuticas	8	US $ 37,5 milhões

Comunicação transparente sobre desenvolvimentos clínicos

Métricas de comunicação:

• 26 Atualizações de ensaios clínicos públicos em 2023
• Webinars trimestrais da comunidade de investidores/pesquisa: 4
• Orçamento de comunicação digital: US $ 890.000

Conferência Científica e Participação do Simpósio

Categoria de conferência	Participação anual	Orçamento de apresentação
Conferências Internacionais	12	US $ 1,2 milhão
Simpósios de pesquisa genética especializados	8	$675,000

Editas Medicine, Inc. (Editar) - Modelo de Negócios: Canais

Publicações científicas diretas

A partir de 2024, a Editas Medicine publicou 37 artigos científicos revisados ​​por pares em periódicos como a biotecnologia da natureza, a ciência e a célula. Fator de impacto total da publicação: 78.6.

Categoria de diário	Número de publicações	Fator de impacto cumulativo
Revistas de engenharia genética	22	45.3
Jornais focados em CRISPR	15	33.3

Apresentações da conferência médica

A Medicina Edita apresentou -se em 14 conferências médicas internacionais em 2023, com 16 apresentações projetadas em 2024.

• Sociedade Americana de Gene & Conferência de terapia celular: 5 apresentações
• Conferência Internacional do CRISPR: 4 apresentações
• Simpósio de pesquisa de doenças raras: 3 apresentações
• Conferência de Medicina Genética: 4 apresentações

Comunicações de Relações com Investidores

Chamadas trimestrais de ganhos: 4 por ano. Deck de apresentação do investidor: 28 slides. Frequência de comunicação do investidor: bimensal.

Tipo de comunicação	Freqüência	Alcançar
Chamadas de ganhos	Trimestral	Mais de 350 investidores institucionais
Webinars de investidores	Bimensal	500+ analistas financeiros

Plataformas científicas digitais

Métricas de engajamento de plataforma on -line para 2024:

• Website Visitantes mensais: 42.500
• Seguidores do LinkedIn: 18.700
• Downloads de conteúdo científico: 6.200 por mês
• Repositório de pesquisa digital: 87 documentos de pesquisa publicados

Anúncios de parceria estratégica

Parcerias estratégicas ativas atuais: 6 instituições farmacêuticas e de pesquisa.

Tipo de parceiro	Número de parcerias	Foco de colaboração
Empresas farmacêuticas	3	Desenvolvimento da terapia genética
Instituições de pesquisa	3	Pesquisa em tecnologia CRISPR

Editas Medicine, Inc. (Editar) - Modelo de negócios: segmentos de clientes

Pacientes com transtorno genético

Mercado endereçável total para distúrbios genéticos: mais de 10.000 condições genéticas raras

Categoria de distúrbio	População estimada de pacientes
Doenças da retina herdadas	50.000 pacientes nos Estados Unidos
Anemia falciforme	100.000 pacientes nos Estados Unidos
Fibrose cística	70.000 pacientes globalmente

Instituições de pesquisa

• Os 20 principais centros de pesquisa acadêmica colaborando ativamente
• Financiamento anual de pesquisa: US $ 15,2 milhões em parcerias institucionais
• Colaborações de pesquisa em tecnologia CRISPR com 12 principais universidades

Empresas farmacêuticas

Potencial de parceria estratégica: 37 grandes empresas farmacêuticas interessadas em tecnologias de edição de genes

Parceiro farmacêutico	Status de colaboração
Pharmaceuticals de vértice	Colaboração ativa
Allergan Pharmaceuticals	Parceria de pesquisa

Centros de tratamento médico

Mercado -alvo: 250 centros de tratamento genético especializados na América do Norte

• Sites de ensaios clínicos: 47 centros médicos ativos
• Centros de tratamento em potencial: 203 metas adicionais

Investidores de biotecnologia

Investimento total em tecnologias de edição de genes: US $ 3,8 bilhões em 2023

Categoria de investidores	Valor do investimento
Capital de risco	US $ 1,2 bilhão
Investidores institucionais	US $ 2,1 bilhões
Private equity	US $ 500 milhões

Editas Medicine, Inc. (Editar) - Modelo de negócios: Estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2022, a Editas Medicine registrou despesas de P&D de US $ 228,3 milhões.

Ano fiscal	Despesas de P&D
2022	US $ 228,3 milhões
2021	US $ 252,4 milhões

Investimentos de ensaios clínicos

A Medicina da Edita alocou aproximadamente US $ 150-180 milhões para ensaios clínicos em andamento em programas de edição de genes durante 2022.

• Programa Clínico Edit-101 para Amaurose Congênica de Leber
• EDIT-301 para doença falciforme
• Edit-302 para beta talassemia

Manutenção de propriedades patentes e intelectuais

Os custos anuais de manutenção da propriedade intelectual foram estimados em US $ 5-7 milhões em 2022.

Desenvolvimento de infraestrutura tecnológica

A infraestrutura tecnológica e os investimentos relacionados totalizaram aproximadamente US $ 15 a 20 milhões em 2022.

Recrutamento e retenção de talentos científicos

Categoria de custo	Despesa anual
Salários	US $ 80-90 milhões
Benefícios	US $ 15-20 milhões
Recrutamento	US $ 3-5 milhões

Estrutura total de custo operacional para 2022: aproximadamente US $ 480-540 milhões

Editas Medicine, Inc. (Editar) - Modelo de negócios: fluxos de receita

Vendas potenciais de produtos terapêuticos

A partir do quarto trimestre 2023, a Editas Medicine não possui produtos comercialmente aprovados. A receita potencial projetada de produtos terapêuticos permanece especulativa.

Acordos de colaboração de pesquisa

Parceiro de colaboração	Valor do acordo	Ano
Juno Therapeutics	Pagamento antecipado de US $ 22 milhões	2018
Bristol Myers Squibb	Pagamento inicial de US $ 30 milhões	2019

Plataformas de tecnologia de licenciamento

Receita de licenciamento da plataforma de edição de genes CRISPR:

• Receita total de licenciamento em 2022: US $ 15,3 milhões
• Receita total de licenciamento em 2023: US $ 12,7 milhões

Financiamento de parceria estratégica

Parceiro	Compromisso total de financiamento	Foco na pesquisa
Pharmaceuticals de vértice	US $ 90 milhões	Anemia falciforme
AstraZeneca	US $ 60 milhões	Metas de oncologia

Concessão e financiamento de pesquisa

• NIH Grants em 2022: US $ 4,2 milhões
• Financiamento da pesquisa da DARPA: US $ 3,5 milhões
• Pesquisa Total Grants 2023: US $ 7,8 milhões

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Value Propositions

You're looking at the core offering from Editas Medicine, Inc., and it centers on delivering potential one-time, durable genomic medicines for serious diseases. This focus on durability is key; think about replacing a chronic treatment regimen with a single intervention. The company's strategy, as of late 2025, heavily emphasizes in vivo gene editing, meaning the therapy is delivered directly into the body to make the edit, rather than removing cells, modifying them outside, and putting them back in (ex vivo).

The differentiation comes from the specific mechanism they are employing for certain targets, like the upregulation strategy. This approach aims to increase the expression of a target protein rather than just fixing a broken one. For their lead candidate, EDIT-401, this means driving up the production of the LDL receptor (LDLR) protein. This strategy is supported by preclinical results showing that only a moderate level of functional editing of LDLR alleles, around 10-40% in the liver, can achieve a massive functional benefit.

The preclinical data for EDIT-401, targeting high LDL cholesterol, is what really anchors this value proposition right now. The numbers from non-human primate (NHP) studies are compelling, showing a rapid and profound effect after just a single dose. Here's the quick math on that proof-of-concept:

Metric	Result in NHPs (Single Dose)
Mean LDL-C Reduction	≥90%
Time to Effect	Within 48 hours
Mean LDLR Protein Increase	≥6-fold
Durability in Mice	Maintained over three months

This in vivo approach is inherently less invasive than the ex vivo cell therapy route, which often requires complex procedures like chemotherapy conditioning and stem cell transplantation. Editas Medicine's strategic shift is evident in their financials; for example, research and development expenses for the three months ended September 30, 2025, decreased by $27.9 million compared to the same period in 2024, partly due to discontinuing the reni-cel program, which was an ex vivo cell medicine. The company is clearly prioritizing the in vivo platform, which they plan to advance with an Investigational New Drug (IND) submission for EDIT-401 by mid-2026, aiming for initial human proof-of-concept data by the end of 2026. Financially, they are positioned to support this focus, with an extended cash runway into the third quarter of 2027, even while reporting a net loss of $25.1 million for Q3 2025, which was an improvement from the $62.1 million loss in Q3 2024. Also, collaboration revenues, like the $7.5 million recognized in Q3 2025 from the BMS agreement, help fund this focused development.

The core benefits you get from this strategy include:

• Potential for a one-time treatment for serious, chronic conditions.
• Delivery via intravenous administration using proprietary targeted lipid nanoparticles (tLNP).
• Focus on upregulation, which can be more potent than simple gene correction.
• Reduced procedural burden compared to ex vivo approaches.

Finance: draft 13-week cash view by Friday.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Customer Relationships

You're managing relationships in the high-stakes world of gene editing, where strategic alliances and clear scientific communication are everything. For Editas Medicine, Inc., the customer relationship structure is heavily weighted toward sophisticated partners and the broader scientific/investor community.

High-touch, strategic management of large pharma collaborations (BMS)

The relationship with Bristol Myers Squibb (BMS) is definitely a cornerstone of the partnership strategy. This is a high-touch management exercise because the deliverables are complex, involving gene-edited T-cell therapies. The depth of this relationship is shown by the sheer volume of programs involved.

Here's a quick look at the scale of the Bristol Myers Squibb relationship as of late 2025:

Collaboration Metric	Value/Status
Programs Opted Into (Total)	13
Gene Targets Covered	11
Programs in IND-Enabling Studies (Q2 2025)	2
Programs in Late-Stage Discovery (Q2 2025)	4
IND/CTA Acceptance (CD19 HD Allo CAR T)	Triggered Milestone Payment in Q2 2025
Collaboration Extension End Date	2026 (with options extending into 2028)

That first IND/CTA acceptance for the CD19 HD Allo CAR T program in Q2 2025 triggered a milestone payment, showing direct financial validation from the partner. Also, revenue recognition related to a milestone achieved under the BMS collaboration was reported in the third quarter of 2025.

Direct communication with investors via press releases and SEC filings

For investors, Editas Medicine, Inc. relies on structured, scheduled disclosures, having moved away from hosting quarterly conference calls. You get your primary updates through official filings and press releases.

Key communication touchpoints in 2025 included:

• Announcing Q3 2025 results on November 10, 2025, via press release and SEC filings.
• Reporting Q1 2025 results on May 12, 2025, through press release and SEC filings.
• The company's cash position as of September 30, 2025, stood at $165.6 million.
• The projected operational cash runway extends into the third quarter of 2027.
• SEC filings in 2025 included a 10-Q on Nov 10 and an 8-K on Oct 9.

The company is defintely using these formal channels to manage expectations about its financial health and pipeline progression.

Scientific engagement through conference presentations and publications

Scientific credibility is a critical relationship builder in this sector, proving the technology works outside the lab. Editas Medicine, Inc. actively engages the scientific community by presenting data at major industry meetings.

Recent scientific engagement included:

• Presenting preclinical data for EDIT-401 at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress in October/November 2025.
• Presenting EDIT-401 data at the American Heart Association (AHA) Scientific Sessions 2025.
• Sharing in vivo preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting in May 2025.
• Presenting data at the TIDES USA 2025 conference in May 2025.
• Sharing new in vivo data in June 2025 at the European Hematology Association (EHA) 2025 Congress.

Looking ahead, management planned to participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, keeping the dialogue open with the investment community.

Finance: draft 13-week cash view by Friday.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Channels

You're looking at how Editas Medicine, Inc. gets its science and corporate story out to the world, from potential pharma partners to the investors watching the ticker. It's a mix of formal scientific exchange and required financial disclosure.

Direct licensing and collaboration agreements with pharmaceutical partners

The channel for deep, long-term value creation is through these partnerships. Revenue recognition here is lumpy, tied to specific milestones being hit. For the three months ended September 30, 2025, Collaboration and other research and development revenues hit $7.5 million, a big jump from just $0.1 million for the same period in 2024. This Q3 2025 revenue spike was mainly due to a milestone achieved under the collaboration agreement with BMS.

The company's technology licensing is also a key channel, particularly the foundational IP. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. Monetizing this IP is active; for instance, Editas Medicine received an upfront cash payment of $57 million from DRI Healthcare Trust by selling certain future license fees related to the Vertex Pharmaceuticals Cas9 agreement. Those future fees range from $5 million to $40 million annually, plus a mid-double-digit percentage of a $50 million contingent upfront payment from Vertex.

Financial Metric/Agreement Detail	Value/Status as of Late 2025
Q3 2025 Collaboration Revenue	$7.5 million
Q3 2024 Collaboration Revenue	$0.1 million
Key Collaboration Partner Triggering Q3 2025 Revenue	BMS (Milestone achieved)
Upfront Payment from DRI for Vertex Fees Monetization	$57 million
Expected Annual License Fees from Vertex (Range)	$5 million to $40 million
Cash, Cash Equivalents, and Marketable Securities (Sep 30, 2025)	$165.6 million
Expected Cash Runway	Into the third quarter of 2027

Scientific conferences (ASGCT, AHA, ESGCT) for data dissemination

Disseminating preclinical data at major scientific venues validates the science. Editas Medicine presented preclinical data on its lead candidate, EDIT-401, at several key meetings in late 2025. The oral presentation at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress (October 7-10, 2025) was led by the Executive Vice President and Chief Scientific Officer, Dr. Linda Burkly. The abstract number for that oral presentation was OR069.

Also, the company presented a moderated digital poster at the American Heart Association (AHA) Scientific Sessions 2025 (November 7-10, 2025). The data presented at both AHA and ESGCT demonstrated over 90% LDL-C reduction in non-human primates with EDIT-401. Earlier in the year, data was presented at the ASGCT annual meeting in May 2025.

Management also used investor conferences as a channel:

• H.C. Wainwright Genetic Medicines Virtual Conference: Fireside Chat on October 14, 2025.
• Chardan 9th Annual Genetic Medicines Conference: Panel Discussion on October 21, 2025.
• 8th Annual Evercore Healthcare Conference: Fireside Chat on December 2, 2025, at 9:10 AM EST.

Regulatory submissions (IND/CTA) to the FDA and other agencies

The path to the clinic is formalized through regulatory filings. Editas Medicine remains on track to submit an Investigational New Drug (IND) or Clinical Trial Application (CTA) for EDIT-401 by mid-2026. The goal is to achieve initial in vivo human proof-of-concept data by year-end 2026.

A key regulatory milestone was already achieved via a partner channel: the first IND/CTA was accepted for the CD19 HD Allo CAR T program, which is part of the collaboration with Bristol Myers Squibb. This acceptance triggered a milestone payment. The company also anticipated establishing one additional target cell type/tissue beyond HSCs and the liver by the end of 2025.

Investor Relations website for corporate and financial updates

The Investor Relations section of www.editasmedicine.com is the primary hub for financial transparency. The company announced its Third Quarter 2025 Results and Business Updates on November 10, 2025, via press release and SEC filings. Importantly, the company stated it does not plan to host quarterly financial results conference calls moving forward.

For public market data as of December 4, 2025, 3:50 PM EST:

Stock Metric	Value
NASDAQ Ticker	EDIT
Closing Price	$2.44
Volume	1,293,645
52 Week High	$4.54
52 Week Low	$0.91
Common Shares Outstanding (Oct 31, 2025)	97,618,660

Webcasts for investor presentations are available live, with archived replays remaining accessible for approximately 30 days following each event.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Customer Segments

You're looking at the customer base for Editas Medicine, Inc. (EDIT) as of late 2025. This is a company deep in the R&D phase, so the 'customers' aren't buying pills yet; they are partners, patients waiting for breakthroughs, and the capital markets funding the journey. Honestly, the segments reflect this high-risk, high-reward biotech reality.

Large pharmaceutical and biotech companies seeking gene editing assets

This segment is crucial because, right now, their revenue is driven by strategic alliances, not product sales. These larger entities provide the capital and potential commercial scale that Editas Medicine, Inc. needs to advance its pipeline. You can see this dependency clearly in the Q3 2025 results, where Collaboration and other research and development revenues hit $7.5 million, a massive jump from the $0.1 million in the same period in 2024. That surge was tied to a milestone achieved under the collaboration agreement with Bristol Myers Squibb (BMS). Also, the company retains rights under a license agreement with Vertex Pharmaceuticals, which contributes to their extended cash runway. These companies are buying access to Editas Medicine, Inc.'s proprietary CRISPR/Cas12a and Cas9 patent estates for human medicines.

Patients with serious genetic diseases with high unmet need (e.g., high LDL-C)

For patients, the value proposition is a potential one-time, transformative therapy. The lead in vivo development candidate, EDIT-401, targets the reduction of LDL cholesterol (LDL-C). The preclinical data is compelling: it showed a mean LDL-C reduction of >90% in non-human primates, which is significantly better than the 40%-60% mean reduction seen with standard of care therapies. The near-term action for this segment is waiting; Editas Medicine, Inc. is on track to submit the Investigational New Drug (IND) or Clinical Trial Application (CTA) for EDIT-401 by mid-2026, aiming for initial human proof-of-concept data by year-end 2026.

Here's a quick look at the pipeline progress and financial backing supporting this patient focus:

Metric	Value / Date	Relevance
EDIT-401 NHP Efficacy	>90% mean LDL-C reduction	Potential superiority over standard of care (40%-60% reduction)
Cash Runway End Date	Third quarter of 2027	Funds operations through key data milestones
Cash, Cash Equivalents, Marketable Securities (as of 9/30/2025)	$165.6 million	Financial stability for R&D progression
Target IND/CTA Submission for EDIT-401	Mid-2026	Timeline to initiate human trials

Clinical investigators and research hospitals for trials

This group is essential for executing the clinical strategy, especially as Editas Medicine, Inc. pivots to in vivo therapies targeting the liver and hematopoietic stem cells (HSCs). While specific numbers of active trial sites aren't public, their engagement is evidenced by the scientific dissemination activities. For instance, preclinical data for EDIT-401 was presented at the American Heart Association (AHA) Scientific Sessions 2025 and the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress. These presentations are how Editas Medicine, Inc. establishes credibility with the investigators who will eventually run their trials.

Institutional and individual investors in the biotech sector

Investors are buying into the potential of the CRISPR technology and the extended financial runway. As of October 31, 2025, the stock price was $3.08, with a market capitalization of $277M based on 97.6M shares outstanding. The ownership structure shows significant institutional interest; there are 327 institutional owners on file. For example, BlackRock, Inc. held 8,019,891 shares as of September 30, 2025. The market is clearly watching the burn rate; the net loss for Q3 2025 was $25.1 million, though this was narrower than the prior year's loss of $62.1 million. The company is actively managing capital, having raised $17.8 million in gross equity proceeds from its ATM facility during Q3 2025.

Investor sentiment is shaped by key financial and operational milestones:

• Stock price on December 3, 2025: $2.36
• Estimated total revenue for the full 2025 fiscal year: $12.67 million
• Number of institutional investors holding positions: 327
• Total Value of Holdings by major institutions (as of 9/30/2025): $105 million
• Net Loss for Q3 2025: $25.1 million

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Cost Structure

You're looking at the major drains on Editas Medicine, Inc.'s cash reserves as they push their in vivo pipeline forward. For a company like Editas Medicine, the Cost Structure is almost entirely driven by the science.

Dominantly Research and Development (R&D) expenses are the single largest cost component. This covers everything from lab work and discovery to preclinical studies and manufacturing scale-up for their gene editing candidates. The focus has clearly shifted following the discontinuation of the reni-cel program.

The R&D spend shows a significant reduction compared to the prior year, reflecting that strategic pivot. For the third quarter ending September 30, 2025, Research and Development expenses were reported at $19.8 million. That's a sharp drop when you compare it to the $47.6 million incurred in the third quarter of 2024. To give you a broader view of the year-to-date trend, the first quarter of 2025 saw R&D expenses of $26.6 million, down from $48.8 million in Q1 2024.

The cost structure was heavily impacted by one-time charges early in the year. The first quarter of 2025 included significant restructuring and impairment charges totaling $40.9 million. These charges were tied directly to the discontinuation of the reni-cel program, covering workforce reductions and impairment of related equipment. For the nine months ended September 30, 2025, the cumulative restructuring and impairment charges amounted to $66.9 million. To be fair, Editas Medicine did not recognize any restructuring and impairment charges in the third quarter of 2025 itself.

Here's a quick look at the operating expense shift:

• Q3 2025 R&D: $19.8 million
• Q3 2024 R&D: $47.6 million
• Q3 2025 G&A: $12.3 million
• Q3 2024 G&A: $18.1 million

General and administrative costs, which cover corporate overhead, executive salaries, and non-R&D related support functions, also saw a reduction as headcount was streamlined. General and administrative expenses for Q3 2025 were $12.3 million, down from $18.1 million in Q3 2024. This reflects the reduced workforce following the December 2024 program discontinuation.

The final major cost category involves Intellectual property maintenance and licensing fees. Editas Medicine is the exclusive licensee for key CRISPR patent estates from the Broad Institute and Harvard University for human medicines. This means they incur ongoing costs to maintain these licenses, including potential milestone payments, success fees, royalty fees, and patent maintenance costs owed to licensors. While the exact recurring expense for these fees in 2025 isn't itemized separately in the high-level releases, these obligations are contingent upon future development and regulatory success.

You can see the material impact of the strategic shift on operating expenses in this comparison:

Expense Category	Period	Amount (USD)
Restructuring and Impairment Charges	Q1 2025 (Three Months)	$40.9 million
Restructuring and Impairment Charges	Nine Months Ended Sept 30, 2025 (YTD)	$66.9 million
Research and Development Expenses	Q3 2025 (Three Months)	$19.8 million
General and Administrative Expenses	Q3 2025 (Three Months)	$12.3 million

Finance: draft 13-week cash view by Friday.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Revenue Streams

You're looking at how Editas Medicine, Inc. funds its operations right now, and honestly, it's all about partnerships and hitting specific targets. For a company deep in the R&D phase, revenue isn't coming from selling a commercial product; it's coming from the value embedded in its intellectual property and the success of its collaborators.

The primary source of top-line income is clearly tied to external agreements. For the third quarter ending September 30, 2025, Collaboration and other R&D revenues hit $7.54 million. That number is a huge jump compared to the $0.1 million recognized in the same period of 2024, showing the lumpy, milestone-driven nature of this income.

Here's a quick look at how that Q3 revenue stacks up against the analyst view for the full year:

Metric	Amount
Q3 2025 Collaboration & R&D Revenue	$7.54 million
Analyst-Estimated Full-Year 2025 Revenue	$12.67 million
Q3 2024 Collaboration & R&D Revenue	$0.1 million

What this estimate hides is that the full-year number relies heavily on hitting future milestones, which is standard for this sector. If onboarding takes longer than expected, that full-year projection could shift.

The key drivers for these revenue events are structured around the value of Editas Medicine's gene editing platform:

• Collaboration and other R&D revenues (Q3 2025: $7.54 million).
• Milestone payments from strategic partners, such as the recognition tied to the Bristol Myers Squibb (BMS) collaboration, specifically following an Investigational New Drug (IND) application acceptance for their CD19 HD Allo CAR T program.
• Licensing and sublicensing revenue from foundational CRISPR IP, evidenced by retained payments under the license agreement with Vertex Pharmaceuticals, which contributes to extending the cash runway.

To be fair, the Q3 surge was almost entirely due to one significant event. The increase was primarily attributable to the recognition of revenue related to a milestone achieved under the Company's collaboration agreement with BMS in the third quarter of 2025. This underscores that revenue visibility is low until a specific development or regulatory event occurs.

Finance: draft 13-week cash view by Friday.